Cell-Free DNA From Nontumor Tissue in Patients With Non-small Cell Lung Cancer

被引：1
|
作者：
Goto, Taichiro [1 ]
机构：
[1] Yamanashi Cent Hosp, Lung Canc & Resp Dis Ctr, Yamanashi, Japan
来源：
CHEST | 2021年 / 160卷 / 04期
关键词：
CIRCULATING TUMOR DNA;
D O I：
10.1016/j.chest.2021.05.072
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：E370 / E371
页数：2
相关论文
共 50 条
  • [31] Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis
    Leng, Shaoyi
    Zheng, Jianjun
    Jin, Yinhua
    Zhang, Hongbin
    Zhu, Ya
    Wu, Jing
    Xu, Yan
    Zhang, Puhong
    CLINICA CHIMICA ACTA, 2018, 477 : 160 - 165
  • [32] Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC)
    Kushnir, M.
    Winter, H.
    Murias, C.
    Bains, P.
    Abbosh, C. Z.
    Papadatos-Pastos, D.
    Newsome-Davis, T.
    Ahmed, T.
    Swanton, C.
    Forster, M. D.
    Moore, D.
    Bennett, P.
    Faull, I.
    Lanman, R. B.
    Arkenau, H-T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Cell-free tumour DNA as a diagnostic and prognostic biomarker in non-small cell lung carcinoma
    Lochowska, Barbara
    Nowak, Dariusz
    Bialasiewicz, Piotr
    ADVANCES IN RESPIRATORY MEDICINE, 2019, 87 (02) : 118 - 122
  • [34] Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
    Szpechcinski, A.
    Chorostowska-Wynimko, J.
    Struniawski, R.
    Kupis, W.
    Rudzinski, P.
    Langfort, R.
    Puscinska, E.
    Bielen, P.
    Sliwinski, P.
    Orlowski, T.
    BRITISH JOURNAL OF CANCER, 2015, 113 (03) : 476 - 483
  • [35] Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
    A Szpechcinski
    J Chorostowska-Wynimko
    R Struniawski
    W Kupis
    P Rudzinski
    R Langfort
    E Puscinska
    P Bielen
    P Sliwinski
    T Orlowski
    British Journal of Cancer, 2015, 113 : 476 - 483
  • [36] Detection of EGFR mutations in circulating cell-free DNA of non-small cell lung cancer patients by next-generation sequencing
    Suzawa, Ken
    Tomida, Shuta
    Matsubara, Takahiro
    Ohashi, Kadoaki
    Maki, Yuho
    Yamamoto, Hiromasa
    Morita, Mizuki
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Kiura, Katuyuki
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    CANCER RESEARCH, 2016, 76
  • [37] Clinical significance of plasma free DNA in patients with non-small cell lung cancer
    Ma, Lanxiang
    Du, Jie
    Sui, Yongjie
    Wang, Shuili
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (11) : 5593 - 5600
  • [38] Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer
    Ohira, Tatsuo
    Sakai, Kazuko
    Matsubayashi, Jun
    Kajiwara, Naohiro
    Kakihana, Masatoshi
    Hagiwara, Masaru
    Hibi, Masaaki
    Yoshida, Koichi
    Maeda, Junichi
    Ohtani, Keishi
    Nagao, Toshitaka
    Nishio, Kazuto
    Ikeda, Norihiko
    CANCER SCIENCE, 2016, 107 (11) : 1660 - 1666
  • [39] EGFR mutation detection in plasma cell-free DNA correlates with clinical outcomes in non-small cell lung cancer
    Shi, J.
    Mong, J.
    Chin, T. M.
    Lim, Y. H.
    Tan, W. L.
    Toh, C. K.
    Tan, H. S.
    Wong, S-W.
    Tee, A.
    Chan, D.
    Wong, K.
    Yeap, S.
    Ngo, L.
    Tan, Y-O.
    Tan, M-H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
    Maria Gabriela O. Fernandes
    Natália Cruz-Martins
    José Carlos Machado
    José Luís Costa
    Venceslau Hespanhol
    Cancer Cell International, 21
12345